bvd-523
Small moleculeexperimental
Clinical trial activity
16 trials · 15 clinical orgs · 0 marketing orgs
Phase 1
9
Phase 2
9
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2013 (NCT01781429)
Timeline
Indications
Studied for
- Colorectal Neoplasms · Phase 1
- Ependymoma · Phase 2
- Gastrointestinal Neoplasms · Phase 2
- Genes · Phase 2
- Glioma · Phase 2
- Healthy Volunteers · Phase 1
- Hepatoblastoma · Phase 2
- Histiocytosis, Langerhans-Cell · Phase 2
- Leukemia, Hairy Cell · Phase 2
- Leukemia, Myeloid, Acute · Phase 1/Phase 2
- Lymphoma · Phase 2
- Lymphoma, Non-Hodgkin · Phase 2
- Medulloblastoma · Phase 2
- Melanoma · Phase 2
- Multiple Myeloma · Phase 2
- Mutation · Phase 2
- Myelodysplastic Syndromes · Phase 1/Phase 2
- Neoplasm Metastasis · Phase 2
- Neoplasms · Phase 2
- Neoplasms, Germ Cell and Embryonal · Phase 2
- Neuroblastoma · Phase 2
- Neuroectodermal Tumors · Phase 2
- Osteosarcoma · Phase 2
- Pancreatic Neoplasms · Phase 1
- Primary Myelofibrosis · Phase 1/Phase 2
- Proto-Oncogene Proteins B-raf · Phase 2
- Rhabdoid Tumor · Phase 2
- Rhabdomyosarcoma · Phase 2
- Sarcoma · Phase 2
- Sarcoma, Ewing · Phase 2
- Wilms Tumor · Phase 2
Mechanism of action
- MAP kinase ERK1INHIBITOR
MAPK3 inhibitor
- MAP kinase ERK2INHIBITOR
MAPK1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)Nc1cc(-c2c[nH]c(C(=O)N[C@H](CO)c3cccc(Cl)c3)c2)c(Cl)cn1- Mol. weight
- 433.34 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3590106 ↗
- ChEMBLCHEMBL3545022 ↗
Also known as
- bvd-523
- bvd-523
- bvd-523
- ulixertinib
- ulixertinib
- vrt-752271
- vrt-752271
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06773195 | Phase 1/Phase 2 (Phase 2) | Jan 7, 2025 | BioMed Valley Discoveries, Inc, Incyte, Memorial Sloan-Kettering Cancer Center |
| NCT06411821 | Phase 2 | May 7, 2024 | BioMed Valley Discoveries, Inc, Memorial Sloan-Kettering Cancer Center |
| NCT05985954 | Phase 1 | Jan 31, 2024 | BioMed Valley Discoveries, Inc, Eli Lilly, University of Texas at Houston |
| NCT05804227 | Phase 1 | Apr 20, 2023 | BioMed Valley Discoveries, Inc, University of Texas at Houston |
| NCT05221320 | Phase 2 | May 26, 2022 | BioMed Valley Discoveries, Inc |
| NCT04488003 | Phase 2 | Nov 3, 2020 | BioMed Valley Discoveries, Inc |
| NCT04145297 | Phase 1 | Jan 30, 2020 | BioMed Valley Discoveries, Inc, University of Utah |
| NCT06400225 | Phase 2 | Jul 24, 2019 | ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI) |
| NCT03698994 | Phase 2 | Oct 1, 2018 | National Cancer Institute (NCI) |
| NCT03417739 | Phase 2 | Mar 26, 2018 | BioMed Valley Discoveries, Inc, Harvard University |
| NCT03454035 | Phase 1 | Jan 30, 2018 | BioMed Valley Discoveries, Inc, Pfizer, University of North Carolina at Chapel Hill |
| NCT02994732 | Phase 1 | Jan 1, 2017 | BioMed Valley Discoveries, Inc, Covance |
| NCT02608229 | Phase 1 | Jun 6, 2016 | BioMed Valley Discoveries, Inc, Washington University in St. Louis |
| NCT02296242 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2014 | BioMed Valley Discoveries, Inc |
| NCT01781429 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2013 | BioMed Valley Discoveries, Inc |
| NCT04566393 | N/A | — | Cancer Commons, xCures |
Showing 16 of 16 trials
Page 1 / 1
Organizations
Research & Development (15)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| BioMed Valley Discoveries, Inc | For profit | 13 | 5 | 2 | 2013 |
| Memorial Sloan-Kettering Cancer Center | Academic/Hospital | 2 | 2 | 1 | 2024 |
| National Cancer Institute (NCI) | Government | 2 | 2 | 1 | 2018 |
| University of Texas at Houston | Academic/Hospital | 2 | 2 | 1 | 2023 |
| Cancer Commons | Academic/Hospital | 1 | 0 | 1 | — |
| Covance | For profit | 1 | 0 | 1 | 2017 |
| ECOG-ACRIN Cancer Research Group | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Eli Lilly | For profit | 1 | 0 | 1 | 2024 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2018 |
| Incyte | For profit | 1 | 0 | 1 | 2025 |
| Pfizer | For profit | 1 | 0 | 1 | 2018 |
| University of North Carolina at Chapel Hill | Academic/Hospital | 1 | 1 | 1 | 2018 |
| University of Utah | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Washington University in St. Louis | Academic/Hospital | 1 | 1 | 1 | 2016 |
| xCures | For profit | 1 | 1 | 1 | — |
15 organizations
Page 1 / 1